Skip to main content
Erschienen in: Rheumatology International 11/2017

16.09.2017 | Validation Studies

Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study)

verfasst von: Agustí Sellas i Fernandez, Xavier Juanola Roura, Alberto Alonso Ruiz, José Rosas, Julio Medina Luezas, Eduardo Collantes Estevez, Miguel Ángel Abad Hernández, Virginia Carrasco Benitez, Cesar Fisac

Erschienen in: Rheumatology International | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

The objective of the study was to study the clinical utility of the Ankylosing Spondylitis Disease Activity Score (ASDAS) for the assessment of disease activity in ankylosing spondylitis (AS) patients, compared to the Bath Ankylosing Spondylitis Activity Index (BASDAI). This was a prospective longitudinal observational study in patients with AS (NY-modified criteria) from 23 Spanish centers. Physical and analytical data; global, lumbar, and nocturnal pain; ASDAS, BASDAI and minimally acceptable clinical status (PASS) were collected. Psychometric characteristics of both indexes were analyzed: construct validity (convergent and divergent), discriminant capacity, criterion validity (global physician and patient assessment), and sensitivity to change. The study involved 127 patients (19.7% attrition). Both BASDAI and ASDAS showed a higher correlation with patient’s global assessment (r = 0.76 and 0.70, respectively) than with physician’s global assessment (r = 0.67 and 0.57). Both scores allowed discriminating patients with an acceptable clinical status, although BASDAI to a greater extent than ASDAS (Cohen δ 1.72 vs 0.88 for the medical PASS). Both scores showed sensitivity to change in patients who changed from an unacceptable symptomatic state to acceptable according to PASS criteria (physician and patient) and by BASDAI 50 response criteria (Cohen δ > 0.80). BASDAI showed better criterion validity than ASDAS, both for the patient PASS (AUC 0.85 vs 0.79) and for the physician’s (AUC 0.90 vs 0.79). ASDAS shows adequate performance for disease activity in patients with AS; however, in this study, its psychometric properties do not present advantages over BASDAI in terms of criterion validity, sensitivity to change or discriminative capacity; replacement of BASDAI by ASDAS is not supported by the data.
Literatur
1.
Zurück zum Zitat Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed
2.
Zurück zum Zitat Haywood KL, Garratt AM, Dawes PT (2005) Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 44(5):577–586CrossRef Haywood KL, Garratt AM, Dawes PT (2005) Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 44(5):577–586CrossRef
3.
Zurück zum Zitat Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM (2004) Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum 51(1):1–8CrossRefPubMed Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM (2004) Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum 51(1):1–8CrossRefPubMed
4.
Zurück zum Zitat Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984PubMed Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984PubMed
5.
Zurück zum Zitat Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H et al (1999) Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over 1 year. J Rheumatol 26(4):997–1002PubMed Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H et al (1999) Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over 1 year. J Rheumatol 26(4):997–1002PubMed
6.
Zurück zum Zitat Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18–24CrossRefPubMed Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18–24CrossRefPubMed
7.
Zurück zum Zitat van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818CrossRefPubMed van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818CrossRefPubMed
8.
Zurück zum Zitat Machado P, Landewe R (2013) Spondyloarthritis: is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol 9(7):388–390CrossRefPubMed Machado P, Landewe R (2013) Spondyloarthritis: is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol 9(7):388–390CrossRefPubMed
9.
Zurück zum Zitat van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMed van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMed
10.
Zurück zum Zitat Collantes E, Fernández Sueiro JL, García-Vicuña R, Gratacós J, Mulero J, Muñoz Fernández S, Sanmartí R, Zarco P, Angel Abad M, Batlle E, de Dios Cañete J, González Crespo MR, González C, Juanola X, Sanz J, Rivera J (2007) Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNFα en las espondiloartritis, incluida la artritis psoriásica. Reumatol Clin 3(Suppl 2):S60–S70. doi:10.1016/S1699-258X(07)73645-8 (Article in Spanish) CrossRefPubMed Collantes E, Fernández Sueiro JL, García-Vicuña R, Gratacós J, Mulero J, Muñoz Fernández S, Sanmartí R, Zarco P, Angel Abad M, Batlle E, de Dios Cañete J, González Crespo MR, González C, Juanola X, Sanz J, Rivera J (2007) Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNFα en las espondiloartritis, incluida la artritis psoriásica. Reumatol Clin 3(Suppl 2):S60–S70. doi:10.​1016/​S1699-258X(07)73645-8 (Article in Spanish) CrossRefPubMed
11.
Zurück zum Zitat Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed
12.
Zurück zum Zitat Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 49(4):483–487CrossRefPubMed Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 49(4):483–487CrossRefPubMed
13.
Zurück zum Zitat Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698PubMed Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698PubMed
14.
Zurück zum Zitat Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F (2004) La versión española del BASDAI es fiable y se correlaciona con la actividad de la enfermedad en pacientes con espondilitis anquilosante. Rev Esp Reumatol 31(6):372–378 Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F (2004) La versión española del BASDAI es fiable y se correlaciona con la actividad de la enfermedad en pacientes con espondilitis anquilosante. Rev Esp Reumatol 31(6):372–378
15.
Zurück zum Zitat Meng XL, Rosenthal R, Rubin DR (1992) Comparing correlated correlation coefficients. Psychological Bull 3(1):172–175CrossRef Meng XL, Rosenthal R, Rubin DR (1992) Comparing correlated correlation coefficients. Psychological Bull 3(1):172–175CrossRef
16.
Zurück zum Zitat Husted JA, Cook RJ, Farewell VT, Gladman DD (2000) Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 53(5):459–468CrossRefPubMed Husted JA, Cook RJ, Farewell VT, Gladman DD (2000) Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 53(5):459–468CrossRefPubMed
17.
Zurück zum Zitat Machado PM, Landewe RB, van der Heijde DM (2011) Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheumatol 38(7):1502–1506CrossRefPubMed Machado PM, Landewe RB, van der Heijde DM (2011) Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheumatol 38(7):1502–1506CrossRefPubMed
18.
Zurück zum Zitat Lekpa FFV, Claudepierre P (2010) Response criteria in spondylarthropathies: definition of a responder. Rev Rhum Monogr 77:52–58 Lekpa FFV, Claudepierre P (2010) Response criteria in spondylarthropathies: definition of a responder. Rev Rhum Monogr 77:52–58
19.
Zurück zum Zitat Pedersen SJ, Sorensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS et al (2010) Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69(6):1065–1071CrossRefPubMed Pedersen SJ, Sorensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS et al (2010) Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69(6):1065–1071CrossRefPubMed
20.
Zurück zum Zitat Aydin SZ, Can M, Atagunduz P, Direskeneli H (2010) Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28(5):752–755PubMed Aydin SZ, Can M, Atagunduz P, Direskeneli H (2010) Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28(5):752–755PubMed
21.
Zurück zum Zitat Spoorenberg A, van Tubergen A, Landewe R, Dougados M, van der Linden S, Mielants H et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 44(6):789–795CrossRef Spoorenberg A, van Tubergen A, Landewe R, Dougados M, van der Linden S, Mielants H et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 44(6):789–795CrossRef
22.
Zurück zum Zitat Fernandez-Espartero C, de Miguel E, Loza E, Tomero E, Gobbo M, Descalzo MA et al (2014) Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis 73(7):1350–1355CrossRefPubMed Fernandez-Espartero C, de Miguel E, Loza E, Tomero E, Gobbo M, Descalzo MA et al (2014) Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis 73(7):1350–1355CrossRefPubMed
23.
Zurück zum Zitat Kilic E, Kilic G, Akgul O, Ozgocmen S (2015) Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int 35(6):981–989CrossRefPubMed Kilic E, Kilic G, Akgul O, Ozgocmen S (2015) Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int 35(6):981–989CrossRefPubMed
24.
Zurück zum Zitat Kilic G, Kilic E, Nas K, Karkucak M, Capkin E, Dagli AZ et al (2015) Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis. Clin Rheumatol 34(3):515–521CrossRefPubMed Kilic G, Kilic E, Nas K, Karkucak M, Capkin E, Dagli AZ et al (2015) Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis. Clin Rheumatol 34(3):515–521CrossRefPubMed
Metadaten
Titel
Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study)
verfasst von
Agustí Sellas i Fernandez
Xavier Juanola Roura
Alberto Alonso Ruiz
José Rosas
Julio Medina Luezas
Eduardo Collantes Estevez
Miguel Ángel Abad Hernández
Virginia Carrasco Benitez
Cesar Fisac
Publikationsdatum
16.09.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 11/2017
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3814-2

Weitere Artikel der Ausgabe 11/2017

Rheumatology International 11/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.